Myomo
Custom powered arm-and-hand braces controlled by remaining muscle signals.
Something off on this page? Send us feedback.
Profile
Sells custom-built powered MyoPro braces that interpret users’ remaining muscle signals to assist weakened or partially paralyzed arms and hands. Revenue combines direct insurer billing with wholesale sales to O&P practices, VA providers, and international accounts, making reimbursement authorization and delivery central to the business.
Designs and custom-fabricates the MyoPro platform, a powered arm-and-hand brace for people with upper-limb weakness or paralysis. Surface sensors interpret remaining muscle signals, then software and motors assist elbow and hand movement. The platform includes Motion W, Motion G, MyoCare training and support, MyoGames practice, MARK2 clinical evaluation, and a connected-care application.
Sells mainly through direct billing, alongside O&P practices, Veterans Health Administration providers, and international distributors. The United States is its principal market and Germany its only individually material foreign market. Its clinical operation evaluates patients, secures insurance authorization, customizes and fits the brace, trains users, and provides follow-up. Revenue timing depends on authorization, delivery, and payer adjudication; the business relies on a single product family, reimbursement coverage, regulated manufacturing, and specialized suppliers.
Company facts
Key statistics
Year to date +62.1% · Average volume (30d) 642.5K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.10 | −$0.07 | +28.6% | $10.4M | $11.7M | +13.1% | +23.58% |
| May 7, 2026Q1 FY26 | −$0.12 | −$0.09 | +25.0% | $9.2M | $10.1M | +9.5% | −5.05% |
| Mar 9, 2026Q4 FY25 | −$0.09 | −$0.08 | +11.1% | $10.4M | $11.4M | +9.1% | −16.80% |
| Nov 10, 2025Q3 FY25 | −$0.11 | −$0.09 | +18.2% | $10.4M | $10.1M | −3.0% | −7.31% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $9.8M | $9.7M | $10.1M | $11.4M | $10.1M | $11.7M | |
| Gross profit | $6.6M | $6.1M | $6.4M | $7.8M | $6.9M | $8.4M | |
| Operating income | −$3.5M | −$4.6M | −$3.5M | −$2.8M | −$3.2M | −$2.3M | |
| Net income | −$3.5M | −$4.6M | −$3.7M | −$3.8M | −$3.0M | −$4.0M | |
| Diluted EPS | −$0.08 | −$0.11 | −$0.09 | −$0.09 | −$0.07 | −$0.09 | |
| Gross margin | 67.2% | 62.7% | 63.8% | 68.6% | 68.2% | 72.1% | |
| Operating margin | -35.8% | -47.6% | -34.9% | -24.4% | -31.2% | -19.3% |
Fiscal years (4-quarter sums)FY24 $32.6M · FY25 $40.9M
Revenue by product · FY24
Balance sheet, Jun 30, 2026Cash & short-term investments $13.5M · Total debt $20.1M · Total assets $35.3M · Shareholders' equity $5.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 38.64M · Float 35.18M · 91.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3.85M | 9.96% | 13F | May 14, 2026 |
| Horton Capital Partners, LLC | 2.31M | 6.00% | 13D | May 18, 2026 |
| BlackRock, Inc. | 1.69M | 4.37% | 13F | May 13, 2026 |
| Paul R. Gudonis · director, officer: Chief Executive Officer | 1.43M | 3.71% | Form 4 | Aug 11, 2026 |
| Vanguard Capital Management LLC | 1.14M | 2.96% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | Harry Kovelman | officer: Chief Medical Officer | −34,750 | $1.73 |
Peers
- Mobia Medical
Stroke-recovery pathway rival for chronic upper-limb impairment.
- Lifeward
Emerging powered upper-body orthosis challenger in stroke care.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Myomo | $1.57 | −2.18% | $61.8M | — | — | 1.4 | +21.3% |
| Mobia Medical | $11.34 | −0.35% | $377.0M | — | — | 14.7 | — |
| Lifeward | $7.47 | +0.13% | $12.0M | — | — | 0.6 | +15.7% |
| Median | — | — | 7.6 | +15.7% |





